https://www.selleckchem.com/pr....oducts/pf-573228.htm
Three participants experienced four serious AEs; none led to DMF discontinuation. Twelve of 17 participants (71%) had no new/newly enlarged T2 lesions from weeks 16-24, two (12%) had one, and one each (6%) had two, three, or five or more lesions [median (range), 0 (0-6)]. Over the full 120-week treatment period, ARR was 0.2, an 84.5% relative reduction (n = 20; 95% confidence interval 66.8-92.8; p less then 0.0001) vs. the year before DMF initiation. Conclusions The long-term safety and efficacy observed in CONNECTED was consistent wi
Like
Comment
Share
